{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental%3A+Test+Product+1", "query": { "intervention": "Experimental: Test Product 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 160, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental%3A+Test+Product+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T20:33:39.563Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05428774", "title": "Efficacy of Different Oral Rehydration Solutions on the Hydration Status of Healthy Males", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fluid Retention", "Beverage Hydration Index", "Hydration Status" ], "interventions": [ { "name": "Test product 1", "type": "OTHER" }, { "name": "Test product 2", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Liquid I.V.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "MALE", "summary": "18 Years to 35 Years · Male only" }, "enrollment_count": 15, "start_date": "2022-08-01", "completion_date": "2023-01-01", "has_results": false, "last_update_posted_date": "2023-01-25", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05428774" }, { "nct_id": "NCT05024097", "title": "A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Etrumadenant (AB928)", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Zimberelimab (AB122)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 43, "start_date": "2022-03-31", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 3, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05024097" }, { "nct_id": "NCT03378102", "title": "Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Allogeneic Hematopoietic Stem Cell Transplantation" ], "interventions": [ { "name": "IFN-gamma-secreting HAdV antigen specific T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mari Dallas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": null, "sex": "ALL", "summary": "3 Months and older" }, "enrollment_count": 20, "start_date": "2019-01-04", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03378102" }, { "nct_id": "NCT06964087", "title": "Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type I Diabetes" ], "interventions": [ { "name": "OPT101", "type": "DRUG" }, { "name": "OPT101 Placebo to Match (PTM)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Op-T LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 72, "start_date": "2026-04-10", "completion_date": "2028-08-19", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06964087" }, { "nct_id": "NCT03074266", "title": "Clinical Performance of the Investigational GEM Hemochron® 100 in Populations Ages 18 Years and Older", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Blood Coagulation Test" ], "interventions": [ { "name": "GEM Hemochron 100 ACT", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Accriva Diagnostics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2017-06-08", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2018-07-26", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 9, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Takoma Park", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03074266" }, { "nct_id": "NCT04070781", "title": "Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Steroid Refractory GVHD", "Graft Vs Host Disease" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1, "start_date": "2020-01-20", "completion_date": "2021-12-13", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04070781" }, { "nct_id": "NCT04606316", "title": "Surgical Nivolumab And Ipilimumab For Recurrent GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "GBM", "Glioblastoma Multiforme", "Grade IV Astrocytoma" ], "interventions": [ { "name": "Nivolumab-Placebo", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab-Placebo", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Patrick Wen, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2021-02-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 4, "location_summary": "Los Angeles, California • Stanford, California • Boston, Massachusetts + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04606316" }, { "nct_id": "NCT06143293", "title": "RESEARCH EVALUATING VAGAL EXCITATION AND ANATOMICAL LINKS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Epilepsy", "Depressive Disorder" ], "interventions": [ { "name": "Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2023-12-15", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 5, "location_summary": "Stanford, California • Minneapolis, Minnesota • St Louis, Missouri + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06143293" }, { "nct_id": "NCT06827236", "title": "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Breast Cancer", "Unresectable Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BNT323", "type": "DRUG" }, { "name": "BNT327", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2025-04-23", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 27, "location_summary": "Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06827236" }, { "nct_id": "NCT06757140", "title": "Opioid Drug Interaction Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Drug Interactions", "Drug Kinetics" ], "interventions": [ { "name": "Alprazolam", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanna Babalonis, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 25, "start_date": "2025-04-01", "completion_date": "2029-06-01", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-23T20:33:39.563Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06757140" } ] }